HOTH - Hoth provides pipeline and regulatory timeline update

Hoth Therapeutics (HOTH) provides pipeline updates and highlights that it has scheduled to start an early-stage clinical trial for its BioLexa Platform, designed for the treatment of atopic dermatitis, in the first quarter of 2021.The company has been granted a Pre-IND meeting with FDA for its HT-001 skin disorder treatment, with responses targeted for February 22, 2021.Hoth also highlighted that key proof-of-concept animal model data for its asthma and allergy treatment HT-004 is expected in Q2 2021.CEO Robb Knie called 2021 an inflection point in Hoth's growth trajectory and said that the company is well-positioned for the year, helped by its unique and diverse portfolio of assets.The company's shares were trading up ~5% premarket.Hoth had announced extension of its research collaboration agreement with Weill Cornell Medicine to continue investigating the therapeutic mechanism of action and safety of HT-003, a novel retinoic acid metabolism blocking agent, for the treatment of acne, the company had said last month.

For further details see:

Hoth provides pipeline and regulatory timeline update